During the past decade, Iop Instituto de Oncologia Do Parana conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Iop Instituto de Oncologia Do Parana" #1 sponsor was "Amgen" with 2 trials, followed by "Clovis Oncology, Inc." with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored and "Taiho Oncology, Inc." with 2 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Iop Instituto de Oncologia Do Parana" #1 collaborator was "Foundation Medicine" with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator and "NSABP Foundation Inc" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Iop Instituto de Oncologia Do Parana" are "Epithelial Ovarian Cancer" (2 trials), "Fallopian Tube Cancer" (2 trials), "Ovarian Cancer" (2 trials), "Peritoneal Cancer" (2 trials) and "Urothelial Cancer" (2 trials). Many other conditions were trialed in "Iop Instituto de Oncologia Do Parana" in a lesser frequency.

Most popular intervention types in "Iop Instituto de Oncologia Do Parana" are "Drug" (7 trials), "Other" (2 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Rucaparib" (2 trials), "AMG 510" (1 trials), "Archival Tumor Tissue Sample" (1 trials) and "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody" (1 trials). Other intervention names were less common.

The vast majority of trials in "Iop Instituto de Oncologia Do Parana" are 8 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Iop Instituto de Oncologia Do Parana". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 3 completed trials in Iop Instituto de Oncologia Do Parana, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Iop Instituto de Oncologia Do Parana, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".